the product in the database has an inactive status
indications:
Infections of the upper and lower respiratory tract (eg tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, pneumonia) caused byHaemophilus influenzae, Klebsiella spp., Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae. Urinary tract infections - cystitis. Sexually transmitted diseases - unexplored urethritis, inflammation in the pelvic region caused byChlamydia trachomatis, Ureaplasma urealitycum. Gastrointestinal infections caused by strainsSalmonella spp., enteropathogenic strainsEscherichia coli (traveler's diarrhea),Entamoeba histolytica, Shigella spp., Vibrio cholerae, Clostridium spp. Infections of the skin and soft tissues, including severe forms of acne vulgaris, caused byClostridium spp., Propionibacterium acnes, Staphylococcus aureus.
Composition:
1 vial contains 100 mg Doxycycline hyclate.
Action:
Tetracycline antibiotic with bacteriostatic activity. Works, among others for Gram-negative bacteria (inclNeisseria gonorrhoeae, Campylobacter granulomatis, Haemophilus ducreyi, Brucella spp.), Gram-positive bacteria (high percentage of resistant strains) and other microorganisms, including atypical bacteria (incl.Chlamydia psittaci and Ch.trachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum), Borrelia recurrentis, Rikettsia spp., Treponema pallidum, Bacillus anthracis, Plasmodium falciparum. Plasma protein binding is 80-90%. It penetrates very well into tissues and body fluids, achieving high concentrations, including in the prostate gland, uterus, ovaries, bladder, bile, bronchi, sinuses and lungs; it also crosses the placenta barrier and into breast milk. Doxycycline is metabolised in the liver and excreted unchanged in the urine and in the form of metabolites in the faeces. T0,5 in the blood is 18-22 h.
Contraindications:
Hypersensitivity to Doxycycline, other tetracyclines or any of the excipients of the preparation. Children under 12 years. Pregnancy (especially the second half).
Precautions:
Doxycycline used in the third trimester of pregnancy, perinatal period or in early childhood may cause discoloration and damage to the teeth. Use with caution in patients with hepatic impairment taking other hepatotoxic drugs or in patients with muscular dystrophy. During the treatment, exposure to UV radiation (sun exposure, solarium) should be avoided due to the risk of photodermatitis. In the event of pseudomembranous colitis caused by doxycycline, the administration of drugs that inhibit intestinal peristalsis or other affecting cells is contraindicated.
Pregnancy and lactation:
Do not use during pregnancy and breast-feeding.
Side effects:
Pain and dizziness, flushing, tinnitus, gastrointestinal disturbances (lack of appetite, nausea, vomiting, diarrhea, abdominal pain, tongue inflammation, difficulty swallowing, esophageal ulceration, inflammation of the intestine, inflammatory changes in the anus), increased urea in the blood, hypersensitivity reactions (symptoms of serum sickness, angioneurotic edema, anaphylactic purpura, hypotension, dyspnea, tachycardia, pericarditis, anaphylactic shock, rash, urticaria, pruritus, photosensitivity, exfoliative dermatitis, Stevens-Johnson syndrome, toxic necrotic separation epidermis), joint and muscle pain, tooth development disorders, enamel discoloration, transient elevation of transaminases in the blood, reactions at the injection site (pain, irritation, burning). Rare: anemia, thrombocytopenia, leukopenia, granulocytosis, porphyria, thrombophlebitis. Very rare: liver dysfunction, hepatitis, jaundice, pancreatitis, relief of fontanelle in infants, intracranial hypertension in adults and children (causing, among others, visual impairment). During long-term use, brown and black discolouration of the thyroid gland was observed, without affecting its performance.During prolonged or repeated treatment - superinfection with resistant microorganisms or fungi (anal pruritis, inflammation of the mouth and tongue, external genital inflammation, vagina). Pseudomembranous colitis, staphylococcal enteritis was also observed.
Dosage:
Doxycycline solution for infusion should only be given if oral therapy is ineffective. After improving the patient's health, it is recommended to continue the treatment with oral form. Adults and children about the month of > 50 kg by intravenous infusion on the first day 0.2 g once or 0.1 g every 12 h, during the following days 0.1 g daily. In severe infections it is given over the entire treatment period of 0.2 g / day. Children over 12 years of age ≤50 kg by intravenous infusion on the first day of 4 mg / kg in 2 divided doses, then 2 mg / kg daily in 1 or 2 doses. The infusion time is 1-4 h, up to 12 h. Treatment should be continued for 24-48 h after symptoms disappear, and for infections caused by β-haemolytic streptococci, the medicine should be administered for at least 10 days.